Xencor, Inc. (NASDAQ:XNCR) Position Boosted by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P increased its position in Xencor, Inc. (NASDAQ:XNCR) by 21.3% in the fourth quarter, Holdings Channel reports. The firm owned 1,092,346 shares of the biopharmaceutical company’s stock after purchasing an additional 192,080 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Xencor were worth $25,102,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of XNCR. Point72 Asset Management L.P. grew its position in shares of Xencor by 147.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock worth $62,748,000 after acquiring an additional 1,858,440 shares in the last quarter. RTW Investments LP bought a new position in Xencor during the third quarter worth $11,563,000. RA Capital Management L.P. acquired a new position in Xencor in the third quarter worth $11,563,000. Braidwell LP bought a new stake in Xencor during the third quarter valued at $9,380,000. Finally, Vanguard Group Inc. lifted its position in shares of Xencor by 5.5% in the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company’s stock worth $184,239,000 after buying an additional 418,040 shares during the last quarter.

Analyst Ratings Changes

Several research firms have recently commented on XNCR. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $20.00 to $30.00 in a report on Monday, December 2nd. StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Finally, Wells Fargo & Company dropped their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $34.38.

Xencor Price Performance

Shares of NASDAQ:XNCR opened at $11.51 on Friday. The firm’s 50 day moving average is $15.72 and its two-hundred day moving average is $20.14. The firm has a market capitalization of $811.02 million, a P/E ratio of -3.60 and a beta of 0.74. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 52 week low of $10.90 and a 52 week high of $27.24.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.